These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16930138)

  • 1. Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
    Mai W; Meng H; Jin J; Wang L
    Eur J Haematol; 2006 Nov; 77(5):445-7. PubMed ID: 16930138
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bortezomib with chemotherapy is highly active in advanced B-precursor acute lymphoblastic leukemia: Therapeutic Advances in Childhood Leukemia & Lymphoma (TACL) Study.
    Messinger YH; Gaynon PS; Sposto R; van der Giessen J; Eckroth E; Malvar J; Bostrom BC;
    Blood; 2012 Jul; 120(2):285-90. PubMed ID: 22653976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Efficacy of chemotherapy combined with bortezomib for two cases of relapsed/refractory acute lymphoblastic leukemia].
    Keino D; Ohyama R; Ashikaga T; Morimoto M; Yamashita A; Kondoh K; Kinoshita A
    Rinsho Ketsueki; 2014 Mar; 55(3):327-33. PubMed ID: 24681936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antitumor effects of bortezomib (PS-341) on primary effusion lymphomas.
    An J; Sun Y; Fisher M; Rettig MB
    Leukemia; 2004 Oct; 18(10):1699-704. PubMed ID: 15343345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.
    Dytfeld D; Matuszak M; Lewandowski K; Komarnicki M
    Ann Hematol; 2008 Mar; 87(3):253-4. PubMed ID: 17955241
    [No Abstract]   [Full Text] [Related]  

  • 6. Phase I study of proteasome inhibitor bortezomib plus CHOP in patients with advanced, aggressive T-cell or NK/T-cell lymphoma.
    Lee J; Suh C; Kang HJ; Ryoo BY; Huh J; Ko YH; Eom HS; Kim K; Park K; Kim WS
    Ann Oncol; 2008 Dec; 19(12):2079-83. PubMed ID: 18689866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.
    Eom HS; Min CK; Cho BS; Lee S; Lee JW; Min WS; Kim CC; Kim M; Kim Y
    Jpn J Clin Oncol; 2009 Jul; 39(7):449-55. PubMed ID: 19487425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials.
    Sonneveld P; Goldschmidt H; Rosiñol L; Bladé J; Lahuerta JJ; Cavo M; Tacchetti P; Zamagni E; Attal M; Lokhorst HM; Desai A; Cakana A; Liu K; van de Velde H; Esseltine DL; Moreau P
    J Clin Oncol; 2013 Sep; 31(26):3279-87. PubMed ID: 23897961
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bortezomib as salvage treatment for heavily pretreated relapsed lymphoma patients: a multicenter retrospective study.
    Zinzani PL; Pellegrini C; Merla E; Ballerini F; Fabbri A; Guarini A; Pavone V; Quintini G; Puccini B; Vigliotti ML; Stefoni V; Derenzini E; Broccoli A; Gandolfi L; Quirini F; Casadei B; Argnani L; Baccarani M
    Hematol Oncol; 2013 Dec; 31(4):179-82. PubMed ID: 23108928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sequence-dependent synergy of the proteasome inhibitor bortezomib and cytarabine in mantle cell lymphoma.
    Weigert O; Pastore A; Rieken M; Lang N; Hiddemann W; Dreyling M
    Leukemia; 2007 Mar; 21(3):524-8. PubMed ID: 17268531
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stringent complete remission of primary plasma cell leukemia with reduced-dose bortezomib, lenalidomide and dexamethasone: a case report and review of the literature.
    Ueda S; Kubo M; Matsuura N; Matsunaga H; Kataoka S; Maeda T; Inui Y; Kawata S; Kanakura Y
    Intern Med; 2013; 52(11):1235-8. PubMed ID: 23728562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasome inhibition with bortezomib: a new therapeutic strategy for non-Hodgkin's lymphoma.
    Leonard JP; Furman RR; Coleman M
    Int J Cancer; 2006 Sep; 119(5):971-9. PubMed ID: 16557600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase 1 dose escalation study of bortezomib combined with rituximab, cyclophosphamide, doxorubicin, modified vincristine, and prednisone for untreated follicular lymphoma and other low-grade B-cell lymphomas.
    Sinha R; Kaufman JL; Khoury HJ; King N; Shenoy PJ; Lewis C; Bumpers K; Hutchison-Rzepka A; Tighiouart M; Heffner LT; Lechowicz MJ; Lonial S; Flowers CR
    Cancer; 2012 Jul; 118(14):3538-48. PubMed ID: 22535574
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Delayed complete remission in a patient with multiple myeloma.
    Ria R; Vacca A; Mangialardi G; Dammacco F
    Eur J Clin Invest; 2008 Dec; 38(12):966-8. PubMed ID: 19021723
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma.
    Zinzani PL; Musuraca G; Tani M; Stefoni V; Marchi E; Fina M; Pellegrini C; Alinari L; Derenzini E; de Vivo A; Sabattini E; Pileri S; Baccarani M
    J Clin Oncol; 2007 Sep; 25(27):4293-7. PubMed ID: 17709797
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of bortezomib in combination with rituximab-HyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma.
    Romaguera JE; Fayad LE; McLaughlin P; Pro B; Rodriguez A; Wang M; Weaver P; Hartig K; Kwak LW; Feldman T; Smith J; Ford P; Goldberg S; Pecora A; Goy A
    Br J Haematol; 2010 Oct; 151(1):47-53. PubMed ID: 20735402
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients.
    Buda G; Orciuolo E; Galimberti S; Pelosini M; Petrini M
    Ann Hematol; 2011 Sep; 90(9):1115-6. PubMed ID: 21181162
    [No Abstract]   [Full Text] [Related]  

  • 18. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.
    Sonneveld P; Schmidt-Wolf IG; van der Holt B; El Jarari L; Bertsch U; Salwender H; Zweegman S; Vellenga E; Broyl A; Blau IW; Weisel KC; Wittebol S; Bos GM; Stevens-Kroef M; Scheid C; Pfreundschuh M; Hose D; Jauch A; van der Velde H; Raymakers R; Schaafsma MR; Kersten MJ; van Marwijk-Kooy M; Duehrsen U; Lindemann W; Wijermans PW; Lokhorst HM; Goldschmidt HM
    J Clin Oncol; 2012 Aug; 30(24):2946-55. PubMed ID: 22802322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination chemotherapy with bortezomib, cyclophosphamide and dexamethasone may be effective for plasma cell leukemia.
    Kim SJ; Kim J; Cho Y; Seo BK; Kim BS
    Jpn J Clin Oncol; 2007 May; 37(5):382-4. PubMed ID: 17538191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab.
    Yan M; Dong Z; Zhao F; Chauncey T; Deauna-Limayo D; Wang-Rodriguez J; Liu D; Wang HY; Pilz R
    Eur J Haematol; 2014 Jul; 93(1):77-80. PubMed ID: 24528507
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.